Mitoxantrone in secondarily progressive multiple sclerosis: a series of 18 patients

Arquivos de Neuro-Psiquiatria

María Belén Montú¹  Walter Oleschko Arruda¹  Marcelo De Souza R. De Oliveira¹  Ricardo Ramina¹ 

[1] ,Instituto de Neurologia de CuritibaCuritiba PR ,Brasil

关键词: mitoxantrone;    multiple sclerosis;    demyelinating disease;    mitoxantrone;    esclerose múltipla;    doença desmielinizante;   

DOI  :  10.1590/S0004-282X2005000200007

来源: SciELO

【 摘 要 】

Mitoxantrone hydrochloride (Novantrone®) is an anthracenedione that has been used as one of the latest in a long line of general immunosuppresive agents studied in multiple sclerosis (MS). We reviewed the clinical, laboratory, neuroimaging and echocardiography data of 18 patients from February 2001 to March 2004 out of a total number of 100 patients with definite MS. Fourteen patients were women (77.7%) and four were men. The mean age of the patients was 41.6±10 years old (confidence intervals 95%: 36.4-46.7 years old). The mean duration of disease was 10.5±6.3 years. Fourteen patients had the secondarily progressive form of MS, and four had the relapsing-remitting form. Mitoxantrone is an useful and clinically effective drug in MS and its major limitation is the potencial cardiotoxicity due to cumulative dose (140 mg).

【 授权许可】

CC BY   
 All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License